Biotech funding froze. Why has this lab instrument maker climbed 25% anyway?
In short
A lab instrument maker has seen its stock climb 25% despite a broader freeze in biotechnology funding. Further details explaining the specific drivers behind the company's market gain were not disclosed in the initial report.
Key points
- A lab instrument maker has seen its stock climb 25% despite a broader freeze in biotechno…: A lab instrument maker has seen its stock climb 25% despite a broader freeze in biotechnology funding.
- Further details explaining the specific drivers behind the company's market gain were not…: Further details explaining the specific drivers behind the company's market gain were not disclosed in the initial report.